Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK or ROS1 non-small cell lung cancer (NSCLC)

S Peters, AT Shaw, B Besse, E Felip, BJ Solomon, RA Soo, A Bearz, SM Gadgee, CC Lin, S Kao, T Seto, ET Masters, A Abbattista, JS Clancy, H Thurm, A Reisman, DR Camidge